A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Fluorouracil (Primary) ; TG 1042 (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- Sponsors Ascend Biopharmaceuticals
- 23 Jan 2017 A combination of 5-FU has been used in the study due to which official title, purpose and treatment are changed hence protocol is amended.
- 23 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2018.
- 07 Nov 2016 According to Biopharmaceuticals media release, Rodney Sinclair is the principal investigator in this study.